See more : Construtora Adolpho Lindenberg S.A. (CALI4.SA) Income Statement Analysis – Financial Results
Complete financial analysis of PAVmed Inc (PAVMZ) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of PAVmed Inc, a leading company in the Medical – Devices industry within the Healthcare sector.
- PT. Anugerah Spareparts Sejahtera Tbk (AEGS.JK) Income Statement Analysis – Financial Results
- Bubalus Resources Limited (BUS.AX) Income Statement Analysis – Financial Results
- Komatsu Ltd. (KMTUY) Income Statement Analysis – Financial Results
- Edda Wind ASA (EWIND.OL) Income Statement Analysis – Financial Results
- Ionic Brands Corp. (IONKF) Income Statement Analysis – Financial Results
PAVmed Inc (PAVMZ)
About PAVmed Inc
PAVmed Inc. operates as a medical device company in the United States. The company's lead products include CarpX, a patented, single-use, disposable, and minimally invasive surgical device for use in the treatment of carpal tunnel syndrome; and EsoCheck, an esophageal cell collection device for the early detection of adenocarcinoma of the esophagus and Barrett's Esophagus (BE); and EsoGuard, a bisulfite-converted next-generation sequencing DNA assay. Its product pipeline also comprises EsoCure, an esophageal ablation device to treat dysplastic BE; PortIO, an implantable intraosseous vascular access device; NextFlo; and Veris cancer care platform. The company was formerly known as PAXmed Inc. and changed its name to PAVmed Inc. in April 2015. PAVmed Inc. was incorporated in 2014 and is headquartered in New York, New York.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 2.45M | 377.00K | 500.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 6.42M | 3.61M | 585.00K | 23.00K | 14.23K | 9.79K | 7.11K | 3.79K | 0.00 | 0.00 |
| Gross Profit | -3.97M | -3.24M | -85.00K | -23.00K | -14.23K | -9.79K | -7.11K | -3.79K | 0.00 | 0.00 |
| Gross Profit Ratio | -161.83% | -858.62% | -17.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 14.28M | 25.55M | 19.85M | 10.96M | 6.63M | 4.25M | 2.62M | 1.72M | 489.33K | 22.29K |
| General & Administrative | 30.95M | 41.04M | 25.57M | 12.39M | 7.66M | 6.31M | 5.42M | 3.93M | 1.29M | 0.00 |
| Selling & Marketing | 17.58M | 19.32M | 8.90M | 2.79M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 48.53M | 60.36M | 34.46M | 12.39M | 7.66M | 6.31M | 5.42M | 3.93M | 1.29M | 400.00K |
| Other Expenses | 2.02M | 1.78M | 0.00 | 0.00 | -558.60K | -903.00K | -3.12M | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 64.83M | 87.69M | 54.31M | 23.35M | 14.30M | 10.56M | 8.03M | 5.65M | 1.78M | 548.77K |
| Cost & Expenses | 71.25M | 91.30M | 54.89M | 23.35M | 14.30M | 10.56M | 8.03M | 5.65M | 1.78M | 548.77K |
| Interest Income | 505.00K | 1.27M | 0.00 | 53.00K | 33.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 589.00K | 1.27M | 0.00 | 53.00K | 32.67K | 2.39M | 724.68K | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 2.93M | 2.55M | 226.00K | 23.00K | 14.23K | 9.79K | 7.11K | 3.79K | 1.78M | 422.29K |
| EBITDA | -75.74M | -99.41M | -55.90M | -35.81M | -16.67M | -12.07M | -11.15M | -5.65M | -1.78M | -126.48K |
| EBITDA Ratio | -3,088.99% | -24,615.92% | -10,833.40% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -68.80M | -90.93M | -54.39M | -23.35M | -14.30M | -10.56M | -8.03M | -5.65M | -1.78M | -422.29K |
| Operating Income Ratio | -2,805.67% | -24,118.57% | -10,878.60% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -10.47M | -12.15M | -1.73M | -12.54M | -2.97M | -7.61M | -1.49M | 0.00 | 0.00 | -126.48K |
| Income Before Tax | -79.26M | -103.24M | -56.13M | -35.89M | -17.27M | -18.17M | -9.52M | -5.65M | -1.78M | -548.77K |
| Income Before Tax Ratio | -3,232.59% | -27,384.08% | -11,225.20% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | -1.94M | -5.78M | -1.56M | -1.34M | -204.07K | 878.87K | -1.00 | -1.78M | -126.48K |
| Net Income | -64.18M | -101.29M | -50.35M | -34.33M | -15.93M | -17.97M | -9.52M | -5.65M | -1.78M | -548.77K |
| Net Income Ratio | -2,617.25% | -26,868.44% | -10,069.40% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -9.16 | -15.03 | -9.80 | -10.93 | -8.31 | -12.63 | -11.56 | -6.53 | -2.36 | -0.96 |
| EPS Diluted | -9.16 | -15.03 | -9.80 | -10.93 | -8.31 | -12.63 | -11.56 | -6.53 | -2.36 | -0.96 |
| Weighted Avg Shares Out | 7.23M | 5.94M | 5.17M | 3.16M | 2.01M | 1.49M | 899.73K | 864.81K | 751.92K | 574.55K |
| Weighted Avg Shares Out (Dil) | 7.23M | 5.94M | 5.17M | 3.16M | 2.01M | 1.49M | 899.73K | 864.81K | 751.92K | 574.55K |
Source: https://incomestatements.info
Category: Stock Reports